Veterinary care is changing fast. With constantly higher standards placed on clinical care, ethical treatment and quality of life. Cavix is dedicated to supporting this positive change by driving the development of therapies that are documented to accelerate healing and ensure predictable outcomes.
The Cavix commercial enterprise begins with the launch of our first proprietary technology: a unique nanosynthetic bone graft for spinal and orthopedic indications in companion animals. Based on a bio-apatite material specifically designed to harness the innate power of osteoimmunology, the nanosynthetic bone graft safely and reliably regenerates bone without having to resort to an autograft - the result of years of academic research and clinical development by leading biomaterial experts and veterinary surgeons in the Cavix founding team.
In parallel to driving the commercialization of our proprietary ready-to use bone graft, our technology platform will continue to expand into complementary veterinary therapies emerging both from our own research as well as from licensing and acquisition.
Based at Green Innovation Park, an innovation hub at the Swedish University for Agricultural and Veterinary Science in Uppsala, our founding team is grounded in advanced research into regenerative technologies for bone defects. Together with world-renowned veterinary surgeons, senior management and founding investors with a proven track record of global commercial development, we’re accelerating the evolution of veterinary care.